INTRODUCTION
The mammalian target of Rapamycin (mTOR) is a 289-kDa serine-threonine kinase that regulates cellular activity (Dazert and Hall, 2011) . mTOR kinases form two distinct multiprotein complexes mTORC1 and mTORC2. Inhibition of mTORC1 alone by rapalogs leads to enhanced activation of PI3K axis by the mTOR-S6K-IRS1-negative feedback loop (Bracho-Valdes et al., 2011) . mTORC2 phosphorylates Akt on Ser473, increasing its enzyme activity up to 10-fold . Activated Akt regulates many cellular functions. Thus, mTORC2 is an attractive target in cancer (Sini et al., 2010; Sparks and Guertin, 2010) .
Keloid disease (KD) is a fibroproliferative lesion characterized by excessive deposition of extracellular matrix (ECM) such as collagen (Shih et al., 2010) , fibronectin (FN), and asmooth muscle actin (a-SMA) (Supplementary Figure S1a online) (Ong et al., 2007) . KD fibroblasts possess cancer-like properties (Vincent et al., 2007) , with overexpression of cytokines and increased angiogenesis (Shih et al., 2010) ( Supplementary Figure S1b online) . KD infiltrates the surrounding tissue with up to 80% recurrence post excision (Mall et al., 2002) . Many treatment modalities exist, but they fail to prevent KD recurrence (Patel and Lawrence Cervino, 2010) , hence the urgency for effective treatment options. mTOR is a regulator of collagen expression in dermal fibroblasts shown by the inhibition of ECM deposition with Rapamycin (Shegogue and Trojanowska, 2004) . The PI3K/Akt/mTOR pathway leads to the overproduction of ECM in KD, and targeting of the mTOR pathway is a potential therapeutic approach in eradicating keloids (Lim et al., 2003; Zhang et al., 2006; Ong et al., 2007) . We hypothesized that dual mTORC1 and mTORC2 inhibition provides superior inhibition of Akt signaling and anti-angiogenic activity. Unlike Rapamycin, which inhibits mTORC1 alone (Benjamin et al., 2011) , here we demonstrate that both KU-0063794 and KU-0068650 (referred to collectively as AstraZeneca (AZ) compounds) are highly selective adenosine triphosphate-competitive inhibitors (Garcia-Martinez et al., 2009 ) of mTOR kinase activity, with no toxicity in vivo (Malagu et al., 2009; Janes et al., 2010; Dormond-Meuwly et al., 2011) , similar in mechanism of action to AZD8055 Sini et al., 2010) . Therefore, we investigated (i) the baseline cellular levels of mTOR, p70S6K, and their activated forms between KD and extra-lesional tissue (ELT) obtained from the same patient, (ii) the effect of both AZ compounds on KD growth and ECM deposition in vitro and ex vivo, and (iii) differences between KU-0063794 and KU-0068650 to a well-recognized mTOR inhibitor Rapamycin.
RESULTS

Overexpression of Total and Phosphorylated forms of mTOR and p70 S6K
There was a differential expression of mTOR and p70 S6K and their phosphorylated forms in KD compared with ELT and extra-lesional fibroblasts (ELFs) (Supplementary Figure S1c online). Total and phosphorylated forms of mTOR showed high expression of both forms in KD compared with ELT ( Figure 1a ). The average total immunoreactivity using In-Cell Western Blotting showed a significant (*Po0.02) increase in mTOR, p-mTOR, p70 S6K , and phospho-p70 S6K (Thr421/ Ser424) in keloid fibroblasts (KFs) compared with ELFs (Figure 1b and c) . Thus, mTOR is active in KD.
Concentration-dependent effect of KU-0063794 and KU-0068650 on PI3K/AKT/mTOR intracellular signaling
The inhibitory potential of both AZ compounds was compared with Rapamycin, an allosteric mTORC1 inhibitor (Benjamin et al., 2011) , in intracellular PI3K/Akt/mTOR signaling of KFs and ELFs. Both AZ compounds demonstrated a dose-dependent, significant (Po0.01) decrease in pAkt-S473. mTORC1 downstream substrates, 4E-BP1, and S6 ribosomal protein were efficiently (Po0.01) dephosphorylated. Both AZ compounds neither inhibited phosphorylated mitogenactivated protein kinase nor pAkt-T308 at a low concentration (2.5 mmol l À 1 ). Furthermore, both AZ compounds reduced (Po0.05) phosphorylation of GSK3b, a critical downstream element of the PI3kinase/Akt and HIF1-a (Po0.01). Rapamycin (20 mmol l À 1 ) significantly reduced pAkt-T308, but had no effect on pAkt-S473 ( Figure 1d ). Both AZ compounds did not cause inhibition of PI3K/Akt/mTOR signaling in ELFs at 2.5 mmol l À 1 ( Supplementary Figure S2 online) . This discrepancy could be due to reduced expression of mTOR and p-mTOR in ELFs compared with KFs. Therefore, both AZ compounds appear specific in the inhibition of pAkt-S473.
Dissociation of mTORC1 and mTORC2 complexes by KU-0063794 and KU-0068650
Both AZ compounds showed a significant (Pp0.01) reduction of p-mTOR, Rictor, and Raptor immunoreactivity ( Figure 1e ).
In contrast, Rapamycin only reduced p-mTOR and Raptor immunoreactivity (Po0.05). To confirm the effect on the mTORC1 and mTORC2 complex observed in KFs, we performed an immunoprecipitation assay. Predictably, both AZ compounds inhibited the association of mTORC1 with Raptor and mTORC2 with Rictor, whereas Rapamycin failed to show mTORC2 inhibition in KFs (Figure 1f ). These results demonstrate that both AZ compounds inhibit mTORC1 and mTORC2 inhibitors as described previously with AZD8055 and P529 (Xue et al., 2008) .
KU-0063794 and KU-0068650 reduced viability/metabolic activity and inhibited cell spreading, attachment, and proliferation in a concentration-dependent manner
The effect of KU-0063794 and KU-0068650 on cell behavior was compared with Rapamycin with the water-soluble tetrazolium salt-1 (WST-1) assay using a range of concentrations. Treatment with different concentrations resulted in significant (Pp0.03) reduction in cell viability/metabolic activity in a dose-dependent manner. However, both AZ compounds had a significantly (Po0.03) higher effect on KFs compared with ELFs. In contrast, Rapamycin showed a similar effect on KFs and ELFs. After compound removal, the effect of Rapamycin recovered in both KFs (Figure 2a ) and ELFs ( Figure 2b ) compared with both AZ compounds.
The cell growth inhibition displayed by both AZ compounds was evaluated using a label-free real-time cell analysis (RTCA) on a microelectronic sensor array (Syed et al., 2012a,b) . Both AZ compounds (Po0.02) and Rapamycin significantly (Po0.05) inhibited cell spreading, attachment, and proliferation in a time-and dose-dependent manner in KFs. Similar dose-dependent and time-dependent inhibitions were also seen in ELFs. In addition, both AZ compounds had a sustained effect on KFs and ELFs seen by the recovery of cells after removal of the inhibitors at 24 hours. When treatment with all three compounds was complete, KFs and ELFs were not able to recover within 26-30 hours compared with the vehicle-treated group. Importantly, in the KU-0068650-treated group, the average cell index was reduced further, suggesting that the effect was sustained in this group. However, in the KU-0063794-and Rapamycin-treated groups, there was an increase in the average cell index in KFs (Figure 2c Figure S3b and c online). Compared with Rapamycin (20 mmol l À 1 ), KU-0063794 and KU-0068650 were highly effective even at a very low concentration (2.5 mmol l À 1 ). Taken together, both AZ compounds significantly (Po0.05) decreased KF and ELF proliferation in a concentration-and time-dependent manner. (e) Both KU-0063794 and KU-0068650 inhibit mTORC1 and mTORC2 in primary KFs. Bar graphs represent the quantification of average protein expression in different treatments from three independent ICWB experiments (n ¼ 6). (f) Co-immunoprecipitation for mTOR with raptor and Rictor to assess TORC1 and TORC2 complex inhibition by both the compounds (n ¼ 11). The data presented here are the means±SEM of triplicate experiments performed. **Po0.05, *Pp0.01 indicate significant difference in the treated group compared with the DMSO control group. AKT, also known as protein kinase B (PKB); 4E-BP1, eukaryotic initiation factor 4 E-binding protein-1; GSK3b, glycogen synthase kinase-3; HIF-1a, hypoxia-inducible factor-1alpha; IP, immunoprecipitation; MAPK, mitogen-activated protein kinase; p-MAPK, phosphorylated mitogen-activated protein kinase; Raptor, regulatory associated protein of mTOR; Rictor, rapamycin-insensitive companion of mTOR.
manner. Rapamycin also reduced the migration of KFs significantly (Po0.05), but at a higher concentration (20 mmol l À 1 ) compared with the vehicle control. However, migration inhibitory effect by both AZ compounds was low in ELFs compared with KFs (Figure 3a and b ). An Oris three-dimensional basement membrane extract invasion and detection assay was used to assess the antiinvasive properties of both AZ compounds. KFs showed a high level of invasion (Po0.01) compared with ELFs. Treatment with both AZ compounds significantly (Po0.01) reduced the invasive properties of KFs at 48 hours post treatment, whereas Rapamycin showed significant (Po0.05) inhibition of KF invasion with a low efficacy compared with both AZ compounds (Figure 3c and d) . These results suggest that both AZ inhibitors have potential anti-invasive properties.
Drug concentrations; KU-0063794 (2.5, 10, 15, and 20 μmol l -1 ) KU-0068650 (2.5, 10, 15, and 20 μmol l -1 ) and rapa (5 and 20 μmol l -1 )
WST-1 at 24 hours drug treatment 5 On the basis of the WST-1 and RTCA results, it was hypothesized that both AZ compounds may achieve their inhibitory effect via apoptosis or cellular necrosis. Indeed, both compounds induced significant apoptosis, as there was an increase in Annexin V-positive cells (Po0.05) at 24 hours post treatment, compared with Rapamycin (5 mmol l À 1 ) and control group, in a concentration-dependent manner. However, higher doses (20 mmol l À 1 ) of Rapamycin also caused significant (Po0.05) apoptosis. Importantly, both AZ compounds caused a reduced level of apoptosis in ELFs compared with KFs ( Supplementary Figure S4a RTCA and WST-1 analyses demonstrated reduced levels of cell proliferation and viability/metabolic activity. The expression levels of cell cycle proteins proliferating cell nuclear antigen and Cyclin D were significant. Concentration-dependent downregulation was observed in fibroblasts treated with both AZ compounds at protein levels. However, Rapamycin showed a significant (Po0.05) reduction in proliferating cell nuclear antigen and Cyclin D expression at a higher concentration compared with vehicle control (DMSO) in KFs and ELFs. Both AZ compounds had a minimal effect on cell cycle proteins at 2.5 mmol l À 1 in ELFs (Figure 4b and Supplementary Figure S5d KU-0063794 and KU-0068650 induced apoptosis and significantly reduced keloid volume and metabolic activity in an ex vivo model
To evaluate the therapeutic potential of both AZ compounds in KD, we used an ex vivo keloid organ culture (OC) model (Bagabir et al., 2012) as described previously. Both AZ compounds (10 mmol l À 1 ) significantly (Pp0.02) induced the shrinkage and reduced the keloid OC volume compared with the vehicle group on day 3. However, Rapamycin treatment (20 mmol l À 1 ) also significantly (Po0.05) decreased the average weight of the keloid OC at week 1 compared with the vehicle group (Figure 4c and Supplementary Figure S6a online). Both AZ compounds (2.5 mmol l À 1 ) and Rapamycin significantly (Po0.05) reduced metabolic activity from day 3 to week 4 as compared with the vehicle group evidenced by an MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (Figure 4d ). Furthermore, both AZ compounds significantly (Po0.02) increased apoptosis on day 3 in situ compared with the Rapamycin-treated group. However, Rapamycin did not cause any significant apoptosis until week 1 post treatment, compared with the vehicle group. At week 4, 55-65% TUNEL-positive cells were observed in both the AZ inhibitor (10 mmol l À 1 )-treated groups, whereas the Rapamycin (20 mmol l À 1 )-treated group showed only 35-40% TUNELpositive cells (Figure 5a and b) . Thus, both AZ compounds caused shrinkage of keloid tissue in an ex vivo model on day 3 post treatment, plus they reduced metabolic activity and induced massive apoptosis at 2.5 mmol l À 1 compared with Rapamycin (20 mmol l À 1 ) in a keloid ex vivo model.
Tissue morphological analysis revealed reduced cellularity/ inflammation and angiogenesis by KU-0063794 and KU-0068650
In hematoxylin and eosin-stained tissue sections, histological changes were evaluated in the epidermis, papillary dermis, and reticular dermis. Up to day 3, the overall tissue architecture was well preserved in the Rapamycin-treated group, whereas at week 1 both AZ compound-treated groups showed reduced cellularity and thinning of the stratum granulosum and papillary dermis. Both KU-0063794-and KU-0068650treated groups showed that the epidermis was completely detached from week 1 to week 4 of treatment and exhibited more intense tissue damage, characterized by keloid cell loss, increased number of cells with pyknotic nuclei, and reduced fibrosis (thick collagen bundles). In contrast, Rapamycin showed minimal effect on keloid OC despite a higher concentration (20 mmol l À 1 ). However, at week 4, Rapamycin-treated explants showed detachment of the epidermis, with increased number of cells showing pyknotic nuclei, although the overall structure was better preserved compared with AZ compound-treated keloid tissue. Both AZ compounds also induced a noticeable decrease in the hyalinized collagen bundles in the keloid tissue model at week 1 through to week 4 ( Supplementary Figure S6b online) .
Keloid tissue shows increased blood vessel density compared with extra-lesional skin ( Supplementary Figure S1b  online) . Therefore, we examined the anti-angiogenic and anti-vascular properties of both AZ compounds. Indeed, these showed a drastic reduction in the number of CD31 þ ve (endothelial cell marker) ( Figure 5c ) and CD34 þ ve (a microvascular endothelial cell marker) cells (Figure 5d ) in the papillary and reticular dermis at week 1 up to week 4. In contrast, Rapamycin showed a noticeable reduction in both anti-CD31 and anti-CD34 expression only at week 4. The above findings suggest that significant shrinkage of keloid tissue in both AZ compound-treated groups may be due to a combination of anti-proliferative and apoptotic effects along with a compound-related anti-angiogenic and anti-vascular effect.
Inhibition of PI3K-Akt-mTOR signaling in keloid OC model by To evaluate the ex vivo effects of both AZ compounds compared with Rapamycin, on intracellular signaling in situ, tissue was analyzed with immunohistochemistry post treatment. In both KU-0063794-and KU-0068650-treated groups, the expression of pAkt-S473 ( Supplementary Figure S7a KU-0063794 and KU-0068650 suppressed pro-collagen, FN biosynthesis, and a-SMA expression in the keloid OC model Finally, we elucidated the potential anti-fibrotic effect of both KU-0063794 and KU-0068650 in keloid OC in situ. As expected, treatment with both AZ inhibitors reduced the immunoreactivity of pro-collagen I at week 1 post treatment compared with the Rapamycin-treated group (Supplementary Figure S8 online) . Similarly, FN was reduced by both AZ compounds on day 3 and week 1 compared with the Rapamycin-treated group (Supplementary Figure S9a online) . We also assessed for the expression of a-SMA, which showed a significant reduction by both the AZ compounds at week 1 up to week 4 (Supplementary Figure S9b online) . Nevertheless, Rapamycin also suppressed the expression level of pro-collagen, FN, and a-SMA at week 1 up to week 4 at a higher concentration compared with the vehicle group. In summary, both AZ compounds caused a significant reduction of ECM-related proteins in keloid tissue compared with Rapamycin.
DISCUSSION
Using in vitro and ex vivo experiments, here we demonstrate two compounds, previously unreported in keloid, KU-0063794 and KU-0068650, that show promising anti-fibrotic activity. Both compounds are not only potent but also selective mTORC1 and mTORC2 inhibitors compared with Rapamycin.
Both AZ compounds attenuated Akt phosphorylation at specific Ser473 and significantly inhibited mTORC1 and mTORC2 complexes, whereas Rapamycin only inhibited the mTORC1 complex. Rapa (20 μmol l -1 ) Rapa (20 μmol l -1 ) KU-0063794 (10 μmol l -1 ) KU-0063794 (10 μmol l -1 ) KU-0063794 (10 μmol l -1 ) KU-0068650 (10 μmol l -1 ) KU-0068650 (10 μmol l -1 ) KU-0068650 (10 μmol l -1 ) DMSO Rapa (20 μmol l -1 ) KU-0063794 (10 μmol l -1 ) KU-0068650 (10 μmol l -1 ) Week 1
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Day 3
Day 3 effective inhibition of KF cell attachment, spreading, proliferation, and caused cytotoxicity and reduced viability/ metabolic activity, as well as inhibited migration and invasion properties at a low concentration (2.5 mmol l À 1 ) compared with Rapamycin (20 mmol l À 1 ). The cell inhibition properties were achieved partly by suppressing proliferating cell nuclear antigen and cyclin D. Reorganization of the actin cytoskeleton is a multistep process and is an early event in cellular activity (Bracho-Valdes et al., 2011) . Both AZ compounds are potent inhibitors of mTORC2 (Jacinto et al., 2004; Bracho-Valdes et al., 2011) , and this may explain the inhibition of keloid cell attachment, spreading, migration, and invasion. In the initial in vitro experiments, using lactate dehydrogenase (cytotoxicity) assay, both AZ compounds showed toxicity in keloid and ELFs. However, the efficacy of both compounds was reduced in ELFs. Importantly, the effect of both compounds was reversible within 24 hours of drug removal in extra-lesional primary fibroblasts but not in KFs (data not shown). From these results, both AZ compounds are highly selective in inhibiting KF activity.
Activation of the PI3K/Akt/mTOR pathway is important for cell growth (Morgensztern and McLeod, 2005) . As the inhibition of PI3K/Akt/mTOR is known to induce apoptosis, both AZ compounds showed severe apoptosis. In contrast, Rapamycin displayed minimal apoptosis. The enhanced ability of both AZ inhibitors to induce apoptosis may explain why both compounds showed higher activity against KF inhibition.
There is increasing evidence that the PI3K/Akt/mTOR network has an important role in ECM regulation in fibrosis (Ong et al., 2007; Dazert and Hall, 2011) . Collagen, FN, and a-SMA are proteins characteristic of the keloid phenotype (Ong et al., 2007; Shih et al., 2010) . Overall, these proteins were selected to assess the effects on ECM production in response to both AZ compounds in KD. Both KU-0063794 and KU-0068650 reduced collagen I, FN, and a-SMA expression in vitro more significantly compared with Rapamycin.
We further explored the antitumour activity of both KU-0063794 and KU-0068650 in an ex vivo model (Bagabir et al., 2012) . Treating the keloid OC with both inhibitors demonstrated histologically reduced cellularity, inflammation, reduced hyalinized collagen bundles, and reduced the average keloid volume in a shrinkage assay. The effect of both compounds on PI3K/Akt/mTOR signaling and angiogenesis showed a significant reduction in p-mTOR and pAkt-S473 levels and significant antiangiogenic properties. Analysis of the effect of both KU-0063794 and KU-0068650 on keloid-associated fibrotic markers showed strong inhibition of collagen I, FN, and a-SMA compared with Rapamycin, at low concentrations in an ex vivo model. KU-0063794 is a potent and highly specific mTOR inhibitor for both mTORC1 and mTORC2, with an IC50 of 10 nM, but it does not suppress the activity of 76 other protein kinases or seven lipid kinases, including Class 1 PI3Ks at 1,000-fold higher concentrations (Garcia-Martinez et al., 2009). In addition, there is no literature available on the efficacy of KU-0068650, which is similar in structure to both KU-0063794 and AZD8055. Moreover, the active form of mTOR (phospho-mTOR) is overexpressed in KD but not in normal skin (Ong et al., 2007; .
Overall, both AZ compounds show significant inhibition of primary KFs at very low concentrations. Indeed, a significant effect by both AZ compounds was only seen in primary normal skin fibroblasts at much higher concentrations, which could have resulted in nonspecific effects on these cells. Thus, the specificity of both AZ compounds is hitherto implied, as both seem to act selectively on cells with active levels of mTOR signaling.
Clinically adverse events have been demonstrated with the use of mTORC1 inhibitor, Sirolimus, and its analogs (Xue et al., 2008; Lewis et al., 2009; Jorge and David, 2011) . However, AZD8055 (a similar compound structurally to both the AZ compounds used in this study) significantly reduced the clonogenic growth of leukemic progenitors from primary CD34 þ Ve AML cells ex vivo. In contrast, exposure to AZD8055 barely affected the clonogenic growth of normal CD34 þ Ve hematopoietic progenitors even at maximal concentrations (Willems et al., 2012) . As both AZ compounds are from a similar family of compounds to AZD8055, it is therefore plausible that both of these compounds may not be toxic to normal cells. However, this assertion remains to be formally tested in both of these AZ compounds. Importantly, it remains to be determined whether these compounds have a real measurable clinical effect on disease tissue in an in vivo scenario before their safe potential use in keloid patients.
Here, we propose a model for the mechanism of action of these compounds on KD ( Supplementary Figure S10 online). The PI3K/Akt/mTOR axis is an important target in keloid pathogenesis, as dual inhibition of mTOR kinases by both the AZ compounds inhibits cell proliferation, migration, and invasion, and causes severe apoptosis compared with an allosteric mTORC1 inhibitor. Thus, both KU-0063794 and KU-0068650 dual mTORC1 and mTORC2 inhibitors may prove to be innovative therapeutic candidates for the treatment of keloid. Interestingly, both compounds showed higher efficacy in keloid compared with non-keloid derived cells. This could be due to active PI3K/ Akt/mTOR axis in KF compared with ELFs, suggesting that both compounds are highly selective for PI3K/Akt/mTOR. Another important observation was that KU-0068650 showed a greater efficacy when compared with KU-0063794 at a similar concentration (2.5 mmol l À 1 ) in every assay, possibly because of higher solubility, the presence of methyl groups, and lower IC50 of KU-0068650 ( Supplementary Table S2 online).
MATERIALS AND METHODS
Patient selection and recruitment
This study was conducted in accordance with the ethical principles of Good Clinical Practice and the Declaration of Helsinki. This study received ethical approval from the local research committee (Manchester, UK), and all subjects gave full written, informed consent. Keloid tissues were harvested at the time of surgery from patients confirmed to have clinical and pathological evidence of KD (Syed et al., 2011; Bagabir et al., 2012) (Supplementary Figure S1c  online) . Thirty-one keloid samples (out of 31 KD samples, 10 samples were used for ex vivo study) ( Supplementary Table S1 online) were ethically consented (ethical approval was obtained from NHS Ethical Committee).
Establishment of primary fibroblast cultures
Keloid and ELTs (Supplementary Figure S1c online) (ELT samples were collected away from the keloid and importantly show no lesional involvement in hematoxylin and eosin) were collected in DMEM using a standard protocol to extract fibroblasts (Syed et al., 2011 Syed and Bayat, 2012a) . In this study, passage 1 (p1) to passage 4 (p4) cells were used.
KU-0063794, KU-0068650, rapamycin, and campothecin compound regime KU-0063794 and KU-0068650 (AstraZeneca, London, UK) ( Supplementary Table S2 online) (2.5; 10; 15; 20 mmol l À 1 ) were compared with Rapamycin (Merck, Middlesex, UK) (5; 20 mmol l À 1 ). Camptothecin (Sigma-Aldrich, Dorset, UK) at a concentration of 250 ng ml À 1 was used as positive control for RTCA, lactate dehydrogenase, WST-1, and apoptotic assays.
High-throughput In-Cell Western Blotting and quantification
Fibroblasts were treated with various concentrations of KU-0063794, KU-0068650, and Rapamycin, and In-Cell Western Blotting was performed using an optimized protocol (Syed and Bayat, 2012a; Syed et al., 2012a,b) . For all antibodies used, see Supplementary Tables S3  and S4 online.
Immunoprecipitation and fluorescent western blotting
Primary KFs (2.5 Â 10 5 cells per well) were grown in 24-well plates for 24 hours. Cells were treated with compounds for 16 hours, and then lysed with cell lysis buffer (1 Â radioimmunoprecipitation assay buffer, Cell Signaling, Hertfordshire, UK). mTOR (1:75) antibody was added and immune complexes were allowed to form by incubating on a rotor overnight at 4 1C. A B50-55% slurry of protein G-Sepharose (Sigma-Aldrich) was added and incubation was carried out for 3 hours at 4 1C. Immunoprecipitates were captured with protein G-Sepharose, washed three times with cell lysis buffer, and analyzed by immunoblotting. Protein concentrations were determined using the bicinchoninic acid protein assay reagent kit (Thermo Scientific, Loughborough, UK). Equal amounts of protein (100 mg per Lane) were separated by NuPAGE Novex Bis-Tris Gels and transferred onto nitrocellulose membranes using iBlot Dry blotting device (Invitrogen, Paisley, UK). Membranes were blocked with blocking buffer (LI-COR, Cambridge, UK) for 30-45 minutes at room temperature. The membranes were incubated with different concentrations of primary antibodies ( Supplementary Table S3 online) overnight at 4 1C. After incubation, the membranes were washed and incubated with secondary antibodies ( Supplementary  Table S4 online) for 1 hour 15 minutes at room temperature. The membranes were washed and the signal was detected using the Odyssey infrared imaging system (LI-COR); b-actin served as loading control.
Label-free RTCA to determine the effect of different concentrations of the compounds
We used a label-free RTCA on a microelectronic system to measure cell attachment, spreading, and proliferation. The basic principle of the RTCA system and the optimized protocol were described previously in detailed (Xing et al., 2005; Syed and Bayat, 2012a; .
In vitro two-dimensional migration assay
The assay was performed as described previously Syed and Bayat, 2012b) . Briefly, a Oris 96-well plate (Oris migration assay kit, Cambridge Bioscience, Cambridge, UK) was coated with 9 mg ml À 1 rat-tail collagen (BD Bioscience, Oxford, UK) and incubated for 30-45 minutes at 37 1C/5% CO 2 . After incubation, Oris cell seeding stoppers were inserted according to the manufacturer's instructions. Serum-starved KFs and ELFs were pre-labeled with PKH26 (Sigma-Aldrich) according to the manufacturer's instructions. A density of 2.5 Â 10 5 cells per well was seeded in each well of the Oris 96-well migration assay plates. The plate was then incubated overnight at 37 1C/5% CO 2 . The next day, the cell seeding stoppers were removed and 100 ml of fresh medium was added with or without different compounds as above; the plates were further incubated and the cells were allowed to migrate for B30 hours in the migration zone. Micrographs were captured using Â 4 magnification of inverted microscopy (Olympus UK, Southend-on-Sea, UK). Cells in the migration zone were counted from four independent experiments and average migrated cells were plotted on the graphs.
In vitro three-dimensional invasion assay
Inhibition of the invasive capacity of KU-0063794, KU-0068650, and Rapamycin was tested using basement membrane extract in vitro in three-dimensional invasion assay (Oris Invasion and detection assay kit, Cambridge Bioscience) as described previously (Syed and Bayat, 2012a; . Briefly, serum-starved cells at a density of 2.5 Â 10 5 cells per well were seeded in Oris invasion assay plates and allowed to attach for 8-12 hours at 371C/5% CO 2 ; after cell attachment, the stoppers were removed from the wells and cells were washed once with phosphate-buffered saline and 40 ml of basement membrane extract was added to the cells. The plates were incubated (at 371C, 5% CO 2 ) for 45-60 minutes. Compound treatments were given for 48 hours and cells were allowed to invade in the 2-mm invasion zone created by Oris cell seeding stoppers. The cells were stained with Calcein AM according to the manufacturer's instructions. Micrographs were captured using Â 4 magnification of inverted Olympus IX71 (Olympus UK Ltd., Southend-on-Sea, UK) microscopy. Invaded cells in the invasion zone were counted from four independent experiments and average invaded cells were plotted on the graphs.
Please see Supplementary data online for methodology used in this study.
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